We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

“Broken skin barriers” are real. They’re the subject of great interest from " skinfluencers " on TikTok, but they’re also ...

Dupixent (dupilumab ... The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection every other week after an initial loading dose, and can be used with or without topical ...

One point in Adbry's favour is that some patients will be able to administer the injectable drug just once per month. after a lead-in period of dosing every other week. Dupixent's label currently ...

Dupixent (dupilumab) was the first biologic treatment approved ... Most people are able to give themselves the injection after they learn how. The injection is typically given into a fatty area around ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

the vast majority of patients who switched to EYLEA HD from a fixed 2-month dosing regimen with EYLEA® (aflibercept) Injection 2 mg maintained visual and anatomic improvements while rapidly ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.